SEC Comment Letter for VERTEX PHARMACEUTICALS (VRTX) — Feb 29, 2008

VERTEX PHARMACEUTICALS INC / MA (VRTX) (CIK 0000875320)
Date: Feb. 29, 2008 · CIK: 0000875320 · Accession: 0000000000-08-010776

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 000-19319

Date

February 29, 2008

Author

Tim Buchmiller

Form

UPLOAD

Company

VERTEX PHARMACEUTICALS INC / MA (VRTX) (CIK 0000875320)

Letter

Mail Stop 6010 February 29, 2008 Kenneth S. Boger Senior Vice President and General Counsel Vertex Pharmaceuticals Incorporated 130 Waverly Street Cambridge, Massachusetts 02139 Re: Vertex Pharmaceuticals Incorporated Definitive Proxy Statement Filed April 12, 2007 File No. 000-19319 Dear Mr. Boger: We have completed our review of your executive compensation and related disclosure and have no further comments at this time. Please note that the company is responsib le for the adequacy and accuracy of the disclosure in its filing. We are not approving any proposed disclosure you may have included in your response lette r or any disclosure you include in your future filings in response to our comments. If you have any further questions regardi ng our review of your filing, please call me at (202) 551-3635. S i n c e r e l y , T i m B u c h m i l l e r S e n i o r A t t o r n e y

Show Raw Text

Mail Stop 6010
  February 29, 2008
 Kenneth S. Boger
Senior Vice President and General Counsel
Vertex Pharmaceuticals Incorporated 130 Waverly Street Cambridge, Massachusetts 02139
Re: Vertex Pharmaceuticals Incorporated  Definitive Proxy Statement
Filed April 12, 2007
 File No. 000-19319
 Dear Mr. Boger:
We have completed our review of your executive compensation and related
disclosure and have no further comments at this time.
Please note that the company is responsib le for the adequacy and accuracy of the
disclosure in its filing.  We  are not approving any proposed  disclosure you may have
included in your response lette r or any disclosure you include in your future filings in
response to our comments.
If you have any further questions regardi ng our review of your filing, please call
me at (202) 551-3635.          S i n c e r e l y ,             T i m  B u c h m i l l e r          S e n i o r  A t t o r n e y

SecProbe.io